Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Sézary syndrome (SS) is a severe form of cutaneous T-cell lymphoma with a poor prognosis despite treatment advances.
• The tumor necrosis factor-α-induced protein 3 (TNFAIP3) gene, also known as A20, plays a role in regulating immune responses and preventing uncontrolled cell growth.

Purpose of the Study:

• To investigate the role of A20 gene alterations in Sézary syndrome.
• To determine the functional impact of A20 inhibition or restoration on T-cell proliferation and cell cycle progression.

Main Methods:

• Genetic analysis to identify deletions in the TNFAIP3 (A20) gene in SS patient samples and cell lines.
• Functional assays to assess the effect of A20 inhibition on NF-κB pathway activation and T-lymphocyte proliferation.
• Experiments to evaluate the impact of A20 expression reconstitution on the cell cycle of SS-derived cells.

Main Results:

• Bi- and monoallelic deletions of the A20 gene were found in a significant proportion of SS patients.
• Biallelic A20 deletion was identified in the SeAx SS cell line.
• Inhibition of A20 led to NF-κB pathway activation and increased normal T-lymphocyte proliferation.
• Reconstitution of A20 expression in SeAx cells resulted in cell cycle arrest.

Conclusions:

• The A20 gene is frequently altered in Sézary syndrome.
• A20 functions as a tumor suppressor in this T-cell malignancy.
• Targeting A20 may offer potential therapeutic strategies for Sézary syndrome.